Anavex Life Sciences Corp.

Equities

AVXL

US0327973006

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.09 USD +0.59% Intraday chart for Anavex Life Sciences Corp. -0.39% -45.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia CI
Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024
Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Anavex Life Sciences Initiates Phase 2 Trial of Schizophrenia Therapy MT
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia CI
Transcript : Anavex Life Sciences Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
Anavex Life Sciences Corp. Provides an Update on Rett Syndrome Program CI
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome CI
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
Anavex Life Sciences Shares Rise on European Approval of Marketing Application for Oral Blarcamesine in Alzheimer's MT
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease CI
Transcript : Anavex Life Sciences Corp., 2023 Earnings Call, Nov 27, 2023
Anavex Life Sciences Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
MORNING BID AMERICAS-Stocks stall after VIX hits pre-COVID low RE
Anavex Life Sciences Secures New Patent for Insomnia, Anxiety Treatment MT
Anavex Life Sciences Begins European Marketing Authorization Process for Blarcamesine to Treat Alzheimer's Disease MT
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer?s Disease to European Medicines Agency CI
Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs CI
Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease CI
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Anavex Life Sciences Says Early Study of Blarcamesine Candidate Showed 'Significant Slowing' in Cognitive Decline in Alzheimer's Patients MT
Chart Anavex Life Sciences Corp.
More charts
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.09 USD
Average target price
40 USD
Spread / Average Target
+685.85%
Consensus